As the inhibitor of the Ras/Raf/MAPK and VEGFR/PDGFR signaling pathway, SOR is able to suppress tumor growth and angiogenesis, thereby delaying HCC progression with the prolongation of the patients' survival for almost 3 months (Tanoglu & Karagoz, 2014). Here, RAF1 is linked to neoplasm.